🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Jinling Hospital, China clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Jinling Hospital, China as lead sponsor. Synced 26 Sep 2026
26Current trials
22Recruiting now
10Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Jinling Hospital, China is the lead sponsor of 26 current clinical trials in our China register. 22 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Toripalimab, Vegfr-Tki and Adebrelimab. The most-studied condition is Carcinoma.

ClinicalTrials.gov trials by status

  • Recruiting2285%
  • Not yet open312%
  • By invitation14%

Trials by phase

  • Phase 2831%
  • Not applicable831%
  • Observational623%
  • Phase 428%
  • Phase EARLY_PHASE128%
01

Clinical trials sponsored by Jinling Hospital, China

26 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma
NCT05917158 · ClinicalTrials.gov ↗ · Carcinoma, Upper Tract Urothelial Carcinoma, UTUC
Phase 2 Recruiting 2022-11 China
Contrast-enhanced Ultrasound and Super-resolution Imaging Predict Renal Function Outcome After Nephrectomy
NCT07294859 · ClinicalTrials.gov ↗ · Nephrectomy, Renal Cell Cancer, AKI - Acute Kidney Injury
Observational Recruiting 2025-09 China
Perioperative Ursodeoxycholic Acid for Renal Protection in Adults Undergoing Partial Nephrectomy for Renal Tumors
NCT07672860 · ClinicalTrials.gov ↗ · Kidney Cancer
Drug: UDCA
Phase 2 Recruiting 2026-06 China
Biologics for Stricturing Crohn's Diseases
NCT05645055 · ClinicalTrials.gov ↗ · The Efficacy of Biologics for Stricturing Crohn's Diseases
Observational Recruiting 2021-01 China
Radial Versus Femoral Access For Thrombectomy in Patients With Acute Basilar Artery Occlusion
NCT05903560 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke
Not applicable Recruiting 2023-07 China
Gut Microbiota Modulation for Immunotherapy Resensitization in Advanced Renal Cell Carcinoma
NCT07611825 · ClinicalTrials.gov ↗ · Advanced RCC
Phase 2 Recruiting 2026-06 China
Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
NCT06676527 · ClinicalTrials.gov ↗ · Neoplasms, Kidney Neoplasms, Urologic Neoplasms
Observational Recruiting 2024-09 China
IDEAL Study: Blinded RCT for the Impact of AI Model for Cerebral Aneurysms Detection on Patients' Diagnosis and Outcomes
NCT06118840 · ClinicalTrials.gov ↗ · Intracranial Aneurysm, CT Angiography, Deep Learning
Not applicable Recruiting 2024-05 China
A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy
NCT06255223 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma, Radiotherapy, Immune Checkpoint Inhibitor
Phase 2 Recruiting 2023-12 China
Comparison of Perioperative Conscious Sedation During Endovascular Thrombectomy in Acute Ischemic Stroke
NCT06139692 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke
Phase 4 Recruiting 2023-11 China
Effect of Remote Ischemic Preconditioning on Early Neurological Deterioration in Acute Perforating Artery Infarction
NCT07237542 · ClinicalTrials.gov ↗ · Ischemic Stroke, Remote Ischaemic Preconditioning
Not applicable Recruiting 2025-12 China
Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma
NCT07571551 · ClinicalTrials.gov ↗ · Clear Cell RCC
Phase 2 Recruiting 2026-05 China
B.Subtilis Attenuate Symptoms in Diarrhea-predominant Irritable Bowel Syndrome by Increasing Hypoxanthine Biosynthesis
NCT06612411 · ClinicalTrials.gov ↗ · Irritable Bowel Syndrome with Diarrhea, Purine Metabolism Disorder
Phase EARLY_PHASE1 Recruiting 2024-06 China
Kidney-protective Intervention With Salt Substitute After Kidney Tumor Surgery
NCT07062952 · ClinicalTrials.gov ↗ · Kidney Tumors, CKD, Salt Substitute
Not applicable Recruiting 2025-04 China
Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer
NCT06326736 · ClinicalTrials.gov ↗ · Pancreatic Cancer
Phase EARLY_PHASE1 Recruiting 2024-04 China
Hyperbaric Oxygen Therapy for Metabolic Dysfunction-associated Steatotic Liver Diseases
NCT06619808 · ClinicalTrials.gov ↗ · Metabolic Dysfunction-associated Steatotic Liver Disease, Hepatic Steatosis, Non-alcoholic Fatty Liver Diseases
Not applicable Recruiting 2024-07 China
Peg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCC
NCT07769827 · ClinicalTrials.gov ↗ · HBV-HCC, Unresectable Advanced HBV-related Liver Cancer
Not applicable Recruiting 2025-12 China
Comparison of Two Stapled Antimesenteric Anastomosis for CD: a Randomized Control Trial Study
NCT05658081 · ClinicalTrials.gov ↗ · Crohn Disease, Recurrence
Not applicable Recruiting 2022-12 China
CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk
NCT07615348 · ClinicalTrials.gov ↗ · Metastatic Clear Cell Renal Cell Carcinoma
Drug: Vegfr-Tki
Phase 2 Recruiting 2026-06 China
Dongzong Cardiovascular Bio-imaging Registry Study
NCT06894095 · ClinicalTrials.gov ↗ · Cardiovascular Diseases, Multi-omics, Living Environments
Observational Recruiting 2023-05 China
PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk
NCT07175480 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma (RCC), Metastatic Renal Cell Carcinoma (mRCC)
Drug: Vegfr-Tki
Phase 2 Recruiting 2025-01 China
Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)
NCT05917106 · ClinicalTrials.gov ↗ · Carcinoma, Renal Cell Carcinoma, RCC
Observational Recruiting 2022-12 China
Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer
NCT06177522 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Neoadjuvant Therapy
Phase 2 Not yet open 2025-11 China
Gastric Feeding for the Prevention of Stroke-Associated Pneumonia
NCT07630090 · ClinicalTrials.gov ↗ · Stroke
Phase 4 Not yet open 2026-06 China
A Study on the Efficacy of Sodium Propionate Combined With Anti-PD-1 Immunotherapy in Gastric Cancer
NCT07615907 · ClinicalTrials.gov ↗ · Gastric Cancer (GC)
Not applicable Not yet open 2026-05 China
Identifying Vulnerable CoronAry PLaqUes With Artificial IntElligence-assisted CT Angiography
NCT06025305 · ClinicalTrials.gov ↗ · Coronary Artery Disease, Plaque, Atherosclerotic
Observational By invitation 2023-07 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Jinling Hospital, China trials

10 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Jinling Hospital, China trials

50 conditions
Carcinoma2Nephrectomy2Acute Ischemic Stroke2Pancreatic Cancer2Kidney Neoplasms2Renal Cell Carcinoma2Upper Tract Urothelial Carcinoma1UTUC1Renal Cell Cancer1AKI - Acute Kidney Injury1Kidney Cancer1The Efficacy of Biologics for Stricturing Crohn's Diseases1Neoadjuvant Therapy1Advanced RCC1Neoplasms1Urologic Neoplasms1Urogenital Neoplasms1Intracranial Aneurysm1CT Angiography1Deep Learning1Double Bind Interaction1Radiotherapy1Immune Checkpoint Inhibitor1Ischemic Stroke1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China2622

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Carcinoma

SponsorTrials
Xuhua Duan1

Sponsors with the most current trials registered for this condition.

06

Questions about Jinling Hospital, China trials

How many clinical trials does Jinling Hospital, China sponsor?

Jinling Hospital, China is the lead sponsor of 26 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Jinling Hospital, China trials recruiting?

Yes. 22 of its 26 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Jinling Hospital, China testing?

Its current trials name 10 drugs and biologicals as interventions. The most frequent are Toripalimab (2), Vegfr-Tki (2), Adebrelimab (1), Albumin-Bound Paclitaxel (1) and Dexmedetomidine (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.